ArticleRespiration; international review of thoracic diseases2025
Increased Risk of Tuberculosis Disease in Lung Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Retrospective Multicenter Study.
Article in Respiration; international review of thoracic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Positive interferon-gamma release assay and immunosuppression: guideline-based diagnosis and treatment of tuberculosis infection].Innere Medizin (Heidelberg, Germany) · 2026Article
- Meta-analysis of tuberculosis incidence and risk in cancer patients treated with immune checkpoint inhibitors.Frontiers in oncology · 2026Article
- Tuberculosis infection following administration of immune checkpoint inhibitors: a real world observational study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: The introduction of immune checkpoint inhibitor (ICI) therapy in lung cancer has improved survival rates, leading to its widespread use. However, there has been a recent increase in case reports of tuberculosis (TB) disease occurrence following ICI treatment. The objective of this study was to ascertain whether the incidence of TB disease is elevated in the ICI group compared to the group receiving platinum-based chemotherapy among all lung cancer patients.
methodsTo compare the risk of TB disease occurrence between the ICI group and the Platinum group in lung cancer patients, a retrospective study was conducted using the clinical data warehouse platform of eight university hospitals affiliated with the Catholic Medical Center in South Korea.
resultsOut of a total of 7,980 patients, those meeting the exclusion criteria were excluded, 991 were categorized into the ICI group, and 3,646 were classified into the Platinum group. The TB disease incidence rate was significantly higher in the ICI group (4.46 per 1,000 person-years) than in the Platinum group (1.12 per 1,000 person-years), with a rate ratio of 3.98 (95% confidence interval [CI]: 1.58-10.00; p = 0.003). Multivariable analysis confirmed ICI therapy as the sole factor significantly associated with TB disease occurrence (adjusted hazard ratio: 3.701, 95% CI: 1.467-9.333; p = 0.006).
conclusionTreatment with ICI in lung cancer patients was associated with a statistically significant increase in the risk of TB disease occurrence compared to conventional platinum-based chemotherapy. Therefore, particularly in patients treated with ICI therapy, prompt respiratory sample tests should be performed for early TB disease diagnosis when new lung lesions are identified. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.